Checking if immunotherapy after surgery helps prevent lung cancer return
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have non-small cell lung cancer and have already completed 2 to 4 cycles of immunotherapy and chemotherapy before surgery, and the surgeon removed all visible cancer
- You have at least one high-risk feature after surgery (your doctor can check this)
- If you have adenocarcinoma, you do not have an EGFR or ALK gene mutation
- You are in good overall health (able to carry out daily activities) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.